Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

580
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
580
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

975
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
975
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.3K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

522
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
522
Overview of the Cardiovascular System01:14

Overview of the Cardiovascular System

12.1K
The cardiovascular system is a vital transportation system in the body. It comprises the heart and blood vessels and facilitates the exchange of gases, nutrients, and waste products.
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
12.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pursuit of advanced fellowships by thoracic surgery residents.

JTCVS open·2026
Same author

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Blood·2026
Same author

Translational insights into Long-COVID: evaluation of preclinical animal models along the lung-brain-immune axis with focus on Golden Syrian Hamsters.

Journal of neuroinflammation·2026
Same author

A Boronic Acid-Based Glutamine Analog Forms a Covalent Adduct with Kidney-Type Glutaminase and Suppresses Triple-Negative Breast Cancer Cell Proliferation.

Biomedicines·2026
Same author

International Society on Thrombosis and Haemostasis conflict of interest management and tools: presentation of a case study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Feb 10, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Nanoparticle Based Treatment for Cardiovascular Diseases.

Purnima Gupta1, Evelyn Garcia1, Amrita Sarkar2

  • 1Department of Immunology, Center for Personalized Nanomedicine, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL-33199, United States.

Cardiovascular & Hematological Disorders Drug Targets
|May 9, 2018
PubMed
Summary

Nanotechnology offers targeted drug delivery for cardiovascular diseases, overcoming conventional therapy limitations. Advanced nanocarriers improve treatment efficacy and reduce side effects for heart conditions like atherosclerosis and myocardial infarction.

Keywords:
Nanomedicinecardiovascular diseasesnanocarriersnanoformulationsnanotechnologytargeted drug delivery systems.

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Related Experiment Videos

Last Updated: Feb 10, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.1K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Area of Science:

  • Cardiovascular Medicine
  • Nanotechnology
  • Pharmacology

Background:

  • Conventional drug delivery for cardiovascular diseases suffers from nonspecificity and severe side effects.
  • Nanocarrier-based drug delivery presents a promising alternative for targeted therapeutic agent delivery to the cardiovascular system.
  • Cardiac disorders like atherosclerosis, hypertension, and myocardial infarction require improved treatment strategies.

Purpose of the Study:

  • To review advanced nanosized drug delivery systems for cardiovascular disorders.
  • To increase understanding of nanotechnology's role in heart-targeted drug delivery.
  • To highlight the potential of nanocarriers in treating cardiac conditions.

Main Methods:

  • Review of existing literature on nanocarrier-based drug delivery systems.
  • Analysis of how nanocarrier physicochemical properties influence in vivo pharmacokinetics and pharmacodynamics.
  • Identification of various nanocarrier types, including lipid and phospholipid nanoparticles, used for cardiac drug delivery.

Main Results:

  • Nanotechnology enables effective therapeutic agent delivery to the cardiovascular system.
  • Nanocarrier modifications (size, shape, surface) significantly impact drug delivery outcomes.
  • Lipid and phospholipid nanoparticles show promise for targeting cardiac sites.

Conclusions:

  • Nanocarrier-based drug delivery is an effective approach for treating cardiovascular disorders.
  • Tailoring nanocarrier properties can optimize treatment strategies for cardiac conditions.
  • Nanotechnology holds significant promise for advancing cardiovascular medicine through targeted drug delivery.